Navigation Links
PharmaFocus: Vaccine Adjuvants in Infectious Disease
Date:4/11/2013

NEW YORK, April 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaFocus: Vaccine Adjuvants in Infectious Disease

http://www.reportlinker.com/p01158403/PharmaFocus-Vaccine-Adjuvants-in-Infectious-Disease.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

PharmaFocus: Vaccine Adjuvants in Infectious Disease

Summary Originally discovered by Glenny in the 1920s, vaccine adjuvants have remained the pharmaceutical industry's "dirty little secret". Today, vaccine adjuvants are credited with helping to bolster the immune response in the host post-vaccination. Recently, second-generation adjuvants have come under scrutiny after reports that the adjuvant used in certain pandemic influenza vaccines was linked to causing narcolepsy in Swedish and British adults. Such reports, compounded by the general mistrust of adjuvants, have resulted in these vital vaccine components becoming the scapegoat of the vaccine industry. However, immunologists and infectious disease specialists are in agreement over the beneficial uses of adjuvants in vaccines today, especially as a means to reduce the number of doses, increase the likelihood of a sustained immunological response and decrease the overall incidence of disease.Scope - Overview of vaccine adjuvants, including the host immune system, host cell targets, descriptions of different adjuvant classes and regulatory guidelines to seek approval for adjuvanted vaccines.

- Key topics covered include vaccines and the host immune response, adjuvant targets, and current adjuvant options (first and second generation) for the vaccine adjuvant market.

- Analysis of the current and future market competition in the vaccine adjuvant market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global vaccine adjuvant market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global vaccine adjuvant market in future.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents 1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 9

2 Introduction 10

2.1 Catalyst 10

3 Vaccines and the Host Immune Response 11

3.1 Vaccines in Infectious Disease 11

3.2 Host Immune Response 12

3.2.1 Primary Barriers Against Infection 12

3.2.2 Innate Immune System 13

3.2.3 Adaptive Immune System 15

3.3 Vaccine Adjuvants 18

3.3.1 Overview 18

3.3.2 Adjuvant Target: Dendritic Cells 19

3.3.3 Adjuvant Target: Toll-Like Receptors 22

3.3.4 Splenic Involvement in Immune Response 25

3.3.5 Antigen-Depot Effect 25

4 Market Drivers and Barriers 27

4.1 Overview 27

4.2 Drivers 28

4.2.1 Driver: Government initiatives to increase vaccination programs 28

4.2.2 Driver: New routes of administration for vaccines 29

4.2.3 Driver: Rapidly mutating pathogens 29

4.2.4 Driver: Recombinant vaccine technology 30

4.2.5 Driver: Increased research efforts against unvaccinated disease 30

4.3 Barriers 31

4.3.1 Barrier: Decreasing or stagnant vaccination rates 31

4.3.2 Barrier: Increasing vaccine prices 32

4.3.3 Barrier: Public opinion of vaccine and adjuvants 33

5 Current Adjuvant Options 34

5.1 Overview 34

5.2 Product Profiles – Major Adjuvant Classes 37

5.2.1 Aluminum Salts (Alum) 37

5.2.2 Emulsions 40

5.2.3 Particulate Delivery Mechanisms 43

5.2.4 Microbial Derivatives 46

5.2.5 Oligonucleotides 49

5.2.6 Adjuvant Systems 52

6 Needs Assessment and Opportunity Analysis 56

6.1 Overview 56

6.2 Unmet Needs Analysis 57

6.2.1 Adjuvant Safety 57

6.2.2 DC Recognition 57

6.2.3 Appropriate TLR Activation 58

6.2.4 Formulation and Dosing 58

6.3 Opportunity Analysis 60

6.3.1 Novel Routes of Administration and Splenic Involvement 60

6.3.2 Combinatorial Adjuvant Systems 61

6.3.3 Limited Use of Antigen Depot 61

7 Clinical Trials and Regulatory Strategy 63

7.1 Clinical Trial Design 63

7.1.1 Non-clinical Evaluation 63

7.1.2 Adjuvant Mechanism of Action Evaluation 64

7.1.3 Clinical Safety Evaluation 64

7.1.4 KOL Opinion on Clinical Design 65

7.2 Regulatory Strategy 67

7.2.1 Overview 67

7.2.2 World Health Organization (WHO) 68

7.2.3 US 69

7.2.4 EU 73

7.2.5 Cultural Differences in Adjuvant Use (US vs. Europe) 73

8 Appendix 75

8.1 Bibliography 75

8.2 Abbreviations 81

8.3 Research Methodology 82

8.4 Physicians and Specialists Included in this Study 83

8.5 About the Authors 85

8.5.1 Author 85

8.5.2 Reviewer 85

8.5.3 Global Head of Healthcare 86

8.6 About GlobalData 86

8.7 Contact Us 86

8.8 Disclaimer 87

List of Tables Table 1: Primary Physical (Epithelial) Barriers to Infection 12

Table 2: Immune Cells and Their Corresponding Toll-like Receptors 15

Table 3: TLR Adjuvant Targets and Ligand Types in Clinical Trials for Infectious Disease Vaccines 24

Table 4: Vaccine Adjuvants – Drivers and Barriers, 2013 27

Table 5: Leading Adjuvants in Clinical Trials for Human Infectious Disease Vaccines 36

Table 6: Product Profile – Aluminum Salts/Alum 38

Table 7: Aluminum Salts/Alum SWOT Analysis, 2013 40

Table 8: Product Profile – Emulsions 42

Table 9: Emulsions SWOT Analysis, 2013 43

Table 10: Product Profile – Particulate Delivery Mechanisms 45

Table 11: Particulate Delivery Mechanisms SWOT Analysis, 2013 46

Table 12: Product Profile – Microbial Derivatives 48

Table 13: Microbial Derivatives SWOT Analysis, 2013 49

Table 14: Product Profile – Oligonucleotides 50

Table 15: Oligonucleotides SWOT Analysis, 2013 52

Table 16: Product Profile – Adjuvant Systems 53

Table 17: GSK's Adjuvant System Portfolio, 2013 53

Table 18: Adjuvant Systems SWOT Analysis, 2013 55

Table 19: Overall Unmet Needs – Current Level of Attainment 56

Table 20: Regulatory Guidelines for the Approval of Adjuvanted Vaccines 72

List of Figures Figure 1: Immune System – Stimulation of Innate and Adaptive Responses 13

Figure 2: Adjuvant Targets – Human Toll-like Receptor Family 23

Figure 3: Adjuvant – Host Immune Response Interactions 35

Figure 4: Chemical Structure of MPL 47

Figure 5: Chemical Structure of Dinitrophenylated CpG ODN 50

Figure 6: WHO Map to Vaccine Adjuvant Usage 69

To order this report:Drug_and_Medication Industry: PharmaFocus: Vaccine Adjuvants in Infectious Disease

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
2. Shingles Vaccine is Safe, According to New Study
3. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
4. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
5. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
6. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
7. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
8. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
9. Global Human Vaccines Industry
10. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
11. HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs Second Generation HIV Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology:
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that really works. ... be incorporated into the post-surgical treatment plans of a variety of other procedures including, ... is very effective for bruising and causes a rapid resolution of bruising and inflammatory ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched its site, ... matching users with high quality water pipes within an ideal price range. The site ... was founded by two brothers, Nick and Mike Hunter, who use medical cannabis to ...
Breaking Medicine News(10 mins):